BTOG is disappointed that lorlatinib has not been recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) in adults who have not had an ALK inhibitor (1st line, CROWN indication).
This recommendation is not intended to affect treatment with lorlatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Click here for full details on the NICE website.